Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer - Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy

Ryuichi Kanai, Keisuke Eguchi, Miwa Takahashi, Steven Goldman, Hideyuki Okano, Takeshi Kawase, Takahito Yazaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Oncolytic herpes vectors like G207 have shown considerable promise in the treatment of solid tumors, but their potency must be enhanced for the full achievement of therapeutic efficacy. Deletion of the innate γ34.5 gene made these vectors extremely safe, but their efficacy was also severely attenuated. Use of tumor-specific promoters is one method to direct toxicity and enhance efficacy against tumors. Recently, Musashi1 has been shown expressed in some tumor tissues. Methods: Eleven human cancer cell lines including five non-small cell lung cancers (NSCLCs) were investigated. Musashi1 mRNA expression was examined by RT-PCR analysis. Western blotting was also performed. Transcriptional activity of P/musashi1 in NSCLCs was assayed by GFP reporter plasmids. Then we constructed a defective amplicon vector containing musashi1 promoter/ICP34.5 with G207 as helper virus (dvM345). In vitro cytotoxicity against NSCLCs and growth characteristics of helper virus were examined. A Lu-99 subcutaneous tumor model was used in an animal study. The tumor volume treated with G207 alone or dvM345 was measured. Results: Musashi1 mRNA was detected in four cell lines. Two in five NSCLCs were positive, and P/musashi1 was proved functional within them. Against these cell lines, dvM345 showed enhanced cytotoxicity, and helper viral growth was augmented. A subcutaneous tumor study confirmed the enhanced therapeutic efficacy of G207 by dvM345 without compromising safety. Conclusions: These results suggest that Musashi1 might be involved in the development of several carcinomas including NSCLC. In the context of oncolytic herpes vector strategy, the P/musashi1 -ICP34,5, method could be used for the treatment of cancers expressing Musashi1.

Original languageEnglish
Pages (from-to)1329-1340
Number of pages12
JournalJournal of Gene Medicine
Volume8
Issue number11
DOIs
Publication statusPublished - 2006 Nov

Fingerprint

RNA-Binding Proteins
Non-Small Cell Lung Carcinoma
Genetic Therapy
Neoplasms
Helper Viruses
Cell Line
Therapeutics
Messenger RNA
Growth
Tumor Burden
Carcinogens
Plasmids
Western Blotting
Carcinoma
Safety
Polymerase Chain Reaction
Genes

Keywords

  • γ34.5 gene
  • Gene therapy
  • Musashi1
  • Non-small cell lung cancer
  • Oncolytic herpes virus vector G207

ASJC Scopus subject areas

  • Genetics

Cite this

Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer - Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. / Kanai, Ryuichi; Eguchi, Keisuke; Takahashi, Miwa; Goldman, Steven; Okano, Hideyuki; Kawase, Takeshi; Yazaki, Takahito.

In: Journal of Gene Medicine, Vol. 8, No. 11, 11.2006, p. 1329-1340.

Research output: Contribution to journalArticle

@article{11f66ab1f9df435787de2302deba6841,
title = "Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer - Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy",
abstract = "Background: Oncolytic herpes vectors like G207 have shown considerable promise in the treatment of solid tumors, but their potency must be enhanced for the full achievement of therapeutic efficacy. Deletion of the innate γ34.5 gene made these vectors extremely safe, but their efficacy was also severely attenuated. Use of tumor-specific promoters is one method to direct toxicity and enhance efficacy against tumors. Recently, Musashi1 has been shown expressed in some tumor tissues. Methods: Eleven human cancer cell lines including five non-small cell lung cancers (NSCLCs) were investigated. Musashi1 mRNA expression was examined by RT-PCR analysis. Western blotting was also performed. Transcriptional activity of P/musashi1 in NSCLCs was assayed by GFP reporter plasmids. Then we constructed a defective amplicon vector containing musashi1 promoter/ICP34.5 with G207 as helper virus (dvM345). In vitro cytotoxicity against NSCLCs and growth characteristics of helper virus were examined. A Lu-99 subcutaneous tumor model was used in an animal study. The tumor volume treated with G207 alone or dvM345 was measured. Results: Musashi1 mRNA was detected in four cell lines. Two in five NSCLCs were positive, and P/musashi1 was proved functional within them. Against these cell lines, dvM345 showed enhanced cytotoxicity, and helper viral growth was augmented. A subcutaneous tumor study confirmed the enhanced therapeutic efficacy of G207 by dvM345 without compromising safety. Conclusions: These results suggest that Musashi1 might be involved in the development of several carcinomas including NSCLC. In the context of oncolytic herpes vector strategy, the P/musashi1 -ICP34,5, method could be used for the treatment of cancers expressing Musashi1.",
keywords = "γ34.5 gene, Gene therapy, Musashi1, Non-small cell lung cancer, Oncolytic herpes virus vector G207",
author = "Ryuichi Kanai and Keisuke Eguchi and Miwa Takahashi and Steven Goldman and Hideyuki Okano and Takeshi Kawase and Takahito Yazaki",
year = "2006",
month = "11",
doi = "10.1002/jgm.965",
language = "English",
volume = "8",
pages = "1329--1340",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer - Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy

AU - Kanai, Ryuichi

AU - Eguchi, Keisuke

AU - Takahashi, Miwa

AU - Goldman, Steven

AU - Okano, Hideyuki

AU - Kawase, Takeshi

AU - Yazaki, Takahito

PY - 2006/11

Y1 - 2006/11

N2 - Background: Oncolytic herpes vectors like G207 have shown considerable promise in the treatment of solid tumors, but their potency must be enhanced for the full achievement of therapeutic efficacy. Deletion of the innate γ34.5 gene made these vectors extremely safe, but their efficacy was also severely attenuated. Use of tumor-specific promoters is one method to direct toxicity and enhance efficacy against tumors. Recently, Musashi1 has been shown expressed in some tumor tissues. Methods: Eleven human cancer cell lines including five non-small cell lung cancers (NSCLCs) were investigated. Musashi1 mRNA expression was examined by RT-PCR analysis. Western blotting was also performed. Transcriptional activity of P/musashi1 in NSCLCs was assayed by GFP reporter plasmids. Then we constructed a defective amplicon vector containing musashi1 promoter/ICP34.5 with G207 as helper virus (dvM345). In vitro cytotoxicity against NSCLCs and growth characteristics of helper virus were examined. A Lu-99 subcutaneous tumor model was used in an animal study. The tumor volume treated with G207 alone or dvM345 was measured. Results: Musashi1 mRNA was detected in four cell lines. Two in five NSCLCs were positive, and P/musashi1 was proved functional within them. Against these cell lines, dvM345 showed enhanced cytotoxicity, and helper viral growth was augmented. A subcutaneous tumor study confirmed the enhanced therapeutic efficacy of G207 by dvM345 without compromising safety. Conclusions: These results suggest that Musashi1 might be involved in the development of several carcinomas including NSCLC. In the context of oncolytic herpes vector strategy, the P/musashi1 -ICP34,5, method could be used for the treatment of cancers expressing Musashi1.

AB - Background: Oncolytic herpes vectors like G207 have shown considerable promise in the treatment of solid tumors, but their potency must be enhanced for the full achievement of therapeutic efficacy. Deletion of the innate γ34.5 gene made these vectors extremely safe, but their efficacy was also severely attenuated. Use of tumor-specific promoters is one method to direct toxicity and enhance efficacy against tumors. Recently, Musashi1 has been shown expressed in some tumor tissues. Methods: Eleven human cancer cell lines including five non-small cell lung cancers (NSCLCs) were investigated. Musashi1 mRNA expression was examined by RT-PCR analysis. Western blotting was also performed. Transcriptional activity of P/musashi1 in NSCLCs was assayed by GFP reporter plasmids. Then we constructed a defective amplicon vector containing musashi1 promoter/ICP34.5 with G207 as helper virus (dvM345). In vitro cytotoxicity against NSCLCs and growth characteristics of helper virus were examined. A Lu-99 subcutaneous tumor model was used in an animal study. The tumor volume treated with G207 alone or dvM345 was measured. Results: Musashi1 mRNA was detected in four cell lines. Two in five NSCLCs were positive, and P/musashi1 was proved functional within them. Against these cell lines, dvM345 showed enhanced cytotoxicity, and helper viral growth was augmented. A subcutaneous tumor study confirmed the enhanced therapeutic efficacy of G207 by dvM345 without compromising safety. Conclusions: These results suggest that Musashi1 might be involved in the development of several carcinomas including NSCLC. In the context of oncolytic herpes vector strategy, the P/musashi1 -ICP34,5, method could be used for the treatment of cancers expressing Musashi1.

KW - γ34.5 gene

KW - Gene therapy

KW - Musashi1

KW - Non-small cell lung cancer

KW - Oncolytic herpes virus vector G207

UR - http://www.scopus.com/inward/record.url?scp=33751231415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751231415&partnerID=8YFLogxK

U2 - 10.1002/jgm.965

DO - 10.1002/jgm.965

M3 - Article

C2 - 16955534

AN - SCOPUS:33751231415

VL - 8

SP - 1329

EP - 1340

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 11

ER -